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DIFFERENT METHODS FOR MODELLING SEVERE HYPOGLYCAEMIC EVENTS: 
IMPLICATIONS FOR EFFECTIVENESS AND COST-EFFECTIVENESS ANALYSES
Keeney E1, Dawoud D2, Dias S1
1University of Bristol, Bristol, UK, 2National Guideline Centre, Royal College of Physicians, London, 
UK
OBJECTIVES: Published clinical trials report severe hypoglycaemic events in dif-
ferent ways. Some report number of patients who suffered at least one event out 
of total number randomised and others report number of events for a given total 
exposure. The different data types can be modelled in different ways; therefore, 
three models have been used in published Bayesian Network Meta Analyses (NMAs) 
of hypoglycaemic events; models with a binomial likelihood reporting odds ratios 
(using a logit link) or hazard ratios (using the complementary log log link) and mod-
els with a Poisson likelihood reporting hazard ratios. The objective of this paper is to 
establish the impact of using different models on effectiveness estimates and the 
outputs from cost-effectiveness models. METHODS: We analysed a dataset used in a 
recent NMA conducted to inform NICE guideline recommendations regarding insu-
lin choice for patients with type 1 diabetes using the three previously used models, 
plus a shared parameter model combining different types of data. RESULTS: The 
relative treatment effects are similar regardless of which model or scale is used. 
Differences were seen when the probability of having an event on the baseline 
treatment was calculated using the different models with the logit model giving a 
baseline probability of 0.07, the clog-log 0.17 and the Poisson 0.29. These translate 
into differences of up to £110 in the cost of a hypoglycaemic event and 0.004 in 
associated disutility when calculating the absolute probabilities of an event to use 
in an economic model. CONCLUSIONS: While choice of outcome measure may not 
have a significant impact on relative effects for this outcome, care should be taken 
to ensure that the baseline probabilities used in an economic model are realistic 
and accurate to avoid over or underestimating costs and effects.
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PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL 
SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Dimopoulos M1, Sonneveld P2, Nahi H3, Kumar S4, Hashim M5, Kulakova M5, Duran M5, 
Heeg B5, Lam A6, Dearden L6
1National and Kapodistrian University of Athens, Athens, Greece, 2Erasmus MC, Rotterdam, 
The Netherlands, 3Karolinska Institute, Stockholm, Sweden, 4Mayo Clinic, Rochester, MN, USA, 
5Ingress Health, Rotterdam, The Netherlands, 6Janssen Global Services, LLC, Raritan, NJ, USA
OBJECTIVES: In a previous study, the quantitative relationship between progression-
free survival (PFS) and overall survival (OS) in multiple myeloma (MM) was assessed. 
However, that analysis combined studies of newly-diagnosed MM and relapsed/
refractory MM (rrMM) and, since that analysis, there have been several randomized 
controlled trials (RCTs) of novel treatments for rrMM. The aim of this study is to 
provide an update of that analysis using randomized controlled trials (RCTs) only 
conducted in rrMM. METHODS: Two bibliographic databases (PubMed and Embase) 
were systematically searched for RCTs published between 1970 to 2017. Firstly, the 
association between median PFS and median OS was assessed using the non-para-
metric Spearman’s rank correlation coefficient. Secondly, the quantitative relation-
ship between PFS and OS was assessed using the Two Stage Least Square (2SLS) 
estimator. This approach was justified by relevant statistical tests in favor of the 
instrumental variable approach. RESULTS: 22 RCTs (42 treatment arms, 7,884 rrMM 
patients) were included. The average median PFS and median OS were 8.26 months 
(SD= 4.85), and 24.34 months (SD= 9.80), respectively. The correlation coefficient of 
median PFS and median OS was 0.712 (P < 0.00001). After adjustment for median 
age, sex and publication year, a 3.10 month (95%CI: 2.20 to 4.00) increase in median 
OS is estimated for each additional month increase in median PFS. CONCLUSIONS: 
Based on newer evidence from RCTs, PFS can be used to predict OS in rrMM and 
this analysis suggests that novel treatments may be providing additional months 
of OS gained for each month of PFS.
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CAN BAYESIAN METHODOLOGY PREDICT LONG-TERM EFFECTIVENESS 
RATHER THAN EFFICACY? AN APPLICATION WITH OVERALL SURVIVAL IN TWO 
ONCOLOGY INDICATIONS
Soikkeli F1, Hashim M1, Mueller S2, Groth A2, Wilke T3, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2Ingress-Health HWM GmbH, Wismar, Germany, 
3INGRESS-Health HWM GmbH, Wismar, Germany
OBJECTIVES: We assessed the impact of combining real-world evidence (RWE) 
with randomized controlled trials (RCTs) data for overall survival (OS) extrapola-
tions. METHODS: Two RCTs in non-small cell lung cancer (NSCLC) and renal cell 
carcinoma (RCC) were selected. Based on the RCT control arms, similar NSCLC 
and RCC populations were identified from a German claims dataset. In WinBUGS, 
parametric survival models were fitted on both RCTs’, and two parametric models 
were fitted over the RWE. We performed two analyses. First, the active treatment 
coefficients from the RCTs’ parametric survival curves were combined with the 
corresponding RWE parameters. Second, the RWE shape parameters were used 
to inform the RCTs’ shape parameters. Several priors were tested. RESULTS: The 
Weibull curve fitted best on both RWE datasets. In RWE, predicted mean OS was 15.5 
(95%CI:13.0-18.8) and 31.4 (95%CI:24.9-42.5) months in NSCLC and RCC, respectively. 
In trials, predicted mean OS was 24.7 (95%CI:18.5-36.2) vs 40.7 (95%CI:28.1-61.2) 
months in NSCLC and 23.9 (95%CI:20.2-28.9) vs 27.9 (95%CI:23.0-35.2) months in 
essential to ensure credibility of the results. The objective was to assess the impact 
of most common calibration methods on cost-effectiveness analysis (CEA): manual, 
Nelder-Mead algorithm and controlled random search (CRS). METHODS: We used a 
previously published and validated model from Spain. Data targets were age-specific 
HPV prevalence and CC incidence. Model outcomes included lifetime risk of cancer, 
quality-adjusted life years (QALYs), and lifetime costs (€ ). We compared the mean 
percentage deviation of model-predicted endpoints from available data for the three 
calibration methods and incremental cost-effectiveness ratios (ICERs) of different 
CC prevention strategies currently under discussion in Europe. RESULTS: Results 
showed that with a non-calibrated random matrix, the deviation was 79%. For the 
manually calibrated matrix, the deviation was 2%, although it required 40 days of 
analyst work. Regarding automatically calibrated matrices, the deviation was about 
7% and 5% with computation times of 25 hours and 100 hours for Nelder-Mead 
and CRS respectively. Although the most cost-effective strategy remained invari-
able based in a CEA threshold of 20,000€ /QALY, the magnitude of ICERs changed 
substantially (7,655€ /QALY-14,745€ /QALY). CONCLUSIONS: Important differences 
in both goodness of fit and CEA are found depending on the calibration approach. 
As was expected, the non-calibrated matrices produced HPV prevalence and CC 
incidence curves very far away from the target values and the largest differences 
on the cost-effectiveness results.
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HOW IRELAND’S COLORECTAL SCREENING PROGRAMME COULD SAVE MORE 
LIVES, SAVE MONEY AND STAY WITHIN EXISTING COLONOSCOPY CAPACITY 
LIMITS: EVIDENCE FROM THE MISCAN MICROSIMULATION MODEL
McFerran E1, O’Mahony JF2
1QUEEN’S UNIVERSITY BELFAST, BELFAST, UK, 2Trinity College Dublin, Dublin, Ireland
OBJECTIVES: To demonstrate why microsimulation modelling of colorectal can-
cer screening indicates that there are likely gains to be made by reconfiguring 
BowelScreen, Ireland’s national colon cancer prevention programme. This analysis 
aims to show how the omission of relevant alternative screening strategies in a 
prior cost-effectiveness analysis of colon cancer screening in Ireland has likely 
led to a sub-optimal policy and that better outcomes at lower cost can be achieved 
by using a lower quantitative cut-off in the faecal immunochemical testing (FIT) 
employed. METHODS: We used the MISCAN microsimulation model of colorectal 
cancer screening to simulate the costs, effects and follow-up colonoscopy capacity 
requirements of 144 alternative screening strategies. These varied in their start and 
stop ages, screening intervals and FIT quantitative cut-off levels. Included in the 
simulations are Ireland’s current programme of biennial screening of 60-69 year-olds 
using a FIT cut-off of 225ng/ml of haemoglobin. We simulate strategies with FIT cut-
offs as low as 50ng/ml. The resulting estimates are plotted in the cost-effectiveness 
plane, checked for dominance and incremental cost-effectiveness ratios are cal-
culated. RESULTS: We find that a combination of a reduction in the FIT cut-off to 
50ng/ml, an extended screening interval of 3 years and a reduced screening start 
age of 55 saves 20% more QALYs, reduces costs by 7%, and yields a 17% reduction 
in colonoscopy requirements. In general, employing a lower FIT cut-off dominates 
strategies with higher cut-offs, such as those currently employed in BowelScreen. 
While extending the screening programme to a larger population would be possible 
and more cost-effective, it requires a lengthening of the screening interval from 
two to three years. CONCLUSIONS: Very simple changes to BowelScreen could save 
many more lives annually, reduce costs and relieve pressure on already constrained 
colonoscopy capacity. This simulation evidence suggests that BowelScreen should 
be re-examined.
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MODELING COVARIATE-ADJUSTED SURVIVAL FOR ECONOMIC EVALUATIONS IN 
ONCOLOGY
Majer IM1, Castaigne J2, Palmer S3, DeCosta L4, Campioni M1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Oncology, Cambridge, UK, 3University of York, 
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OBJECTIVES: Survival data from randomized controlled trials (RCT) is routinely 
extrapolated for economic evaluations in oncology. Imbalances in prognostic and/
or predictive factors across treatment arms should be adjusted to generate unbiased 
estimates. To date no formal guidance has been developed regarding how such 
adjustments should be made. We compared various covariate-adjusted survival 
modeling approaches, based on parametric regression and propensity score match-
ing, applied to the ENDEAVOR RCT in multiple myeloma that assessed carfilzomib-
dexamethasone (Cd) versus bortezomib-dexamethasone (Vd). METHODS: Overall 
survival (OS) data and baseline characteristics were used for a subgroup (borte-
zomib-naïve/one prior therapy) reflecting the population where Cd is recommended 
in England and Wales. The following adjusted survival modeling approaches were 
compared: multiple Weibull regression model including prognostic/predictive 
covariates jointly fitted to the two arms to predict survival i) using the mean value 
of each covariate and ii) using the average of patient-specific survival predictions; 
iii) applying an adjusted hazard ratio derived from a Cox proportional hazard model 
to the baseline risk estimated for Vd with a Weibull model; iv) propensity score 
matching followed by fitting a Weibull model to the two arms of the balanced data 
including treatment group as the only covariate (matched data approach). RESULTS: 
The difference in mean OS estimated by the matched data approach was 2.06 
years (0.02-5.01) with the smallest variance among the estimates. Despite other 
approaches estimated similar differences, the mean OS appeared biased (using 
the mean value of each covariate yielded skewed survival estimates), had limited 
external validity (implausible long-term OS predictions), and required assumptions 
not statistically appropriate, e.g. proportional hazards were not satisfied for all 
covariates. CONCLUSIONS: Adjusted survival modeling based on matched data 
approaches provides a flexible and robust method to correct for covariate imbal-
ances in economic evaluations. The conclusions of our study may be generalizable 
to other settings.
